Sucampo Pharmaceuticals Obtains FDA Approval For AMITIZA(R) For The Treatment Of Irritable Bowel Syndrome With Constipation In Adult Women

Sucampo Pharmaceuticals, Inc., (NASDAQ: SCMP, Sucampo Pharmaceuticals) and Takeda Pharmaceutical Company Limited (TSE: 4502, Takeda) and its wholly owned subsidiary, Takeda Pharmaceuticals North America, Inc., announced that the U.S.

More: continued here

Filed under: Irritable-Bowel Syndrome on May 15th, 2008